Mandrake Bio, a pioneering startup in the field of foundational protein design, has successfully raised Rs 16 crore in pre-seed funding. The round was co-led by Activate and Antler, with additional support from Spectrum Impact, DeVC, and several angel investors from the AI and biotech sectors. This funding is significant as it underscores the growing interest and investment in biotechnology startups in India, particularly those at the intersection of AI and biological sciences.
### Mandrake Bio’s Innovative Approach
Founded in 2025 by Tanay Lohia and Dr. Kutubuddin Molla, Mandrake Bio is at the forefront of designing programmable gene-editing enzymes. The startup’s platform leverages a combination of generative AI and biophysics to create novel gene-editing tools. This approach allows for the engineering of protein structures with high precision and dynamic control, which are essential for impactful applications in agriculture and medicine. The funding will be utilized to further develop their AI-driven protein-design platform, expand their research team, and enhance wet-lab validation processes for agricultural and medical applications.
### The Competitive Landscape
Mandrake Bio operates within a competitive environment where biotechnology and AI-driven innovations are rapidly gaining traction. Globally, companies like Mammoth Biosciences and CRISPR Therapeutics are pioneering similar technologies, but Mandrake aims to distinguish itself through its unique integration of AI with foundational biophysics. The ability to design proteins from scratch presents a significant competitive edge, potentially reducing the time and cost associated with developing new agricultural products and medical therapies.
### Implications for India’s Startup Ecosystem
The successful funding round for Mandrake Bio is indicative of a larger trend within India’s startup ecosystem, where there is increasing support for deep-tech ventures. This aligns with the national focus on fostering innovation in biotechnology and AI, driven by both private investment and supportive government policies. The involvement of prominent investors and industry veterans in Mandrake’s funding round highlights the confidence in India’s ability to produce globally competitive biotech solutions. This can inspire more startups to explore intersections of AI and life sciences, potentially positioning India as a leader in cutting-edge biotech research and development.
As Mandrake Bio progresses with its development plans, stakeholders in the biotech and investment community will be keenly watching its advancements. For founders and investors, the startup’s journey could provide valuable insights into the potential and challenges of integrating AI with biotechnology. The next phase for Mandrake Bio will involve scaling its operations and proving the efficacy of its technology in real-world applications, which will be crucial in securing further investment and achieving commercial success.
